To support advances in MS research, Anaspec is providing MOG (35-55), a key peptide that induces severe chronic experimental autoimmune encephalomyelitis in transgenic mice.
Anaspec claims its MOG (35-55) peptide from mouse and rat sequence (cat# 60130) has been shown to induce anti-MOG (35-55) autoantibody production in C57BL/6 mice at 100 per cent incidence (10/10), indicating that this peptide is a suitable choice for in vivo anti-MOG (35-55) auto antibody study.
In addition to this peptide, Anaspec provides a large selection of MOG peptides of varied sequences and lengths, as well as MBP (myelin basic protein) and PLP (proteolipid proteins) peptides, which are two other potential primary encephalitogenic target antigens in multiple sclerosis.
